Funder: National Institutes of Health
Due Dates: June 2, 2025 (New, Renewal, Resubmission) | May 1, 2025 (Letter of Intent) | June 2, 2026 (New, Renewal, Resubmission) | May 1, 2026 (Letter of Intent)
Funding Amounts: Up to $275,000 direct costs over 2 years (max $200,000 in any single year); 3–5 awards anticipated; total NIH commitment up to $1.2M in FY26.
Summary: Supports preclinical efficacy, pharmacodynamic, and pharmacokinetic studies of therapeutic agents in established rare disease models to advance candidates toward IND-enabling development or clinical trials.
Key Information: Clinical trials are not allowed; model development is not supported; a partnership plan with a rare disease steering/oversight committee is required.